# Structure Therapeutics Inc.: financial statements, quarterly

GPCR · Nasdaq · CIK 1888886 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/gpcr.md) · [Financials](/companies/gpcr/financials.md) · [Filings](/companies/gpcr/filings.md) · [Insiders](/companies/gpcr/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/gpcr/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Research and development | $m | [17.5](/filings/0001558370-24-015531.md) | [20.0 d](/filings/0001104659-26-020562.md) | [20.7](/filings/0001558370-25-006989.md) | [22.1](/filings/0001558370-25-010541.md) | [32.6](/filings/0001104659-25-107829.md) | [33.5 d](/filings/0001104659-26-020562.md) | [42.9](/filings/0001104659-26-057230.md) | [54.7](/filings/0001104659-26-092057.md) | [59.0](/filings/0001104659-25-107829.md) | [68.7 d](/filings/0001104659-26-020562.md) | [66.5](/filings/0001104659-26-057230.md) | [100](/filings/0001104659-26-092057.md) |
| Operating income | $m | [(26.1)](/filings/0001558370-24-015531.md) | [(31.0) d](/filings/0001104659-26-020562.md) | [(32.0)](/filings/0001558370-25-006989.md) | [(33.3)](/filings/0001558370-25-010541.md) | [(45.8)](/filings/0001104659-25-107829.md) | [(47.1) d](/filings/0001104659-26-020562.md) | [(56.3)](/filings/0001104659-26-057230.md) | [(70.5)](/filings/0001104659-26-092057.md) | [(73.8)](/filings/0001104659-25-107829.md) | [24.0 d](/filings/0001104659-26-020562.md) | [(89.4)](/filings/0001104659-26-057230.md) | [(119)](/filings/0001104659-26-092057.md) |
| Income tax | $m | [0.4](/filings/0001558370-24-015531.md) | [(0.3) d](/filings/0001104659-26-020562.md) | [0.0](/filings/0001558370-25-006989.md) | [0.1](/filings/0001558370-25-010541.md) | [0.1](/filings/0001104659-25-107829.md) | [0.1 d](/filings/0001104659-26-020562.md) | [0.1](/filings/0001104659-26-057230.md) | [0.1](/filings/0001104659-26-092057.md) | [0.1](/filings/0001104659-25-107829.md) | [0.2 d](/filings/0001104659-26-020562.md) | [0.2](/filings/0001104659-26-057230.md) | [0.2](/filings/0001104659-26-092057.md) |
| Net income | $m | [(23.9)](/filings/0001558370-24-015531.md) | [(24.5) d](/filings/0001104659-26-020562.md) | [(26.0)](/filings/0001104659-25-107829.md) | [(26.0)](/filings/0001104659-25-107829.md) | [(34.0)](/filings/0001104659-25-107829.md) | [(36.5) d](/filings/0001104659-26-020562.md) | [(46.8)](/filings/0001104659-26-092057.md) | [(61.7)](/filings/0001104659-26-092057.md) | [(65.7)](/filings/0001104659-25-107829.md) | [33.0 d](/filings/0001104659-26-020562.md) | [(76.0)](/filings/0001104659-26-092057.md) | [(106)](/filings/0001104659-26-092057.md) |
| Diluted EPS | $ per share | [(0.21)](/filings/0001558370-24-015531.md) | not reported | [(0.19)](/filings/0001558370-25-006989.md) | [(0.18)](/filings/0001558370-24-011616.md) | [(0.20)](/filings/0001104659-25-107829.md) | not reported | [(0.27)](/filings/0001104659-26-057230.md) | [(0.36)](/filings/0001104659-26-092057.md) | [(0.37)](/filings/0001104659-25-107829.md) | not reported | [(0.35)](/filings/0001104659-26-057230.md) | [(0.49)](/filings/0001104659-26-092057.md) |
| Basic EPS | $ per share | [(0.21)](/filings/0001558370-24-015531.md) | not reported | [(0.19)](/filings/0001558370-25-006989.md) | [(0.18)](/filings/0001558370-25-010541.md) | [(0.20)](/filings/0001104659-25-107829.md) | not reported | [(0.27)](/filings/0001104659-26-057230.md) | [(0.36)](/filings/0001104659-26-092057.md) | [(0.37)](/filings/0001104659-25-107829.md) | not reported | [(0.35)](/filings/0001104659-26-057230.md) | [(0.49)](/filings/0001104659-26-092057.md) |

- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [50.6](/filings/0001558370-23-019203.md) | [130](/filings/0001558370-25-001826.md) | [97.8](/filings/0001558370-24-007642.md) | [382](/filings/0001558370-24-011616.md) | [172](/filings/0001558370-24-015531.md) | [170](/filings/0001104659-26-020562.md) | [152](/filings/0001558370-25-006989.md) | [147](/filings/0001558370-25-010541.md) | [103](/filings/0001104659-25-107829.md) | [800](/filings/0001104659-26-092057.md) | [316](/filings/0001104659-26-057230.md) | [273](/filings/0001104659-26-092057.md) |
| Current assets | $m | [210](/filings/0001558370-23-019203.md) | [474](/filings/0001558370-25-001826.md) | [449](/filings/0001558370-24-007642.md) | [938](/filings/0001558370-24-011616.md) | [924](/filings/0001558370-24-015531.md) | [891](/filings/0001104659-26-020562.md) | [850](/filings/0001558370-25-006989.md) | [799](/filings/0001558370-25-010541.md) | [814](/filings/0001104659-25-107829.md) | [1,570](/filings/0001104659-26-092057.md) | [1,491](/filings/0001104659-26-057230.md) | [1,372](/filings/0001104659-26-092057.md) |
| Total assets | $m | [216](/filings/0001558370-23-019203.md) | [482](/filings/0001558370-25-001826.md) | [457](/filings/0001558370-24-007642.md) | [947](/filings/0001558370-24-011616.md) | [933](/filings/0001558370-24-015531.md) | [903](/filings/0001104659-26-020562.md) | [867](/filings/0001558370-25-006989.md) | [816](/filings/0001558370-25-010541.md) | [832](/filings/0001104659-25-107829.md) | [1,584](/filings/0001104659-26-092057.md) | [1,508](/filings/0001104659-26-057230.md) | [1,425](/filings/0001104659-26-092057.md) |
| Current liabilities | $m | [20.1](/filings/0001558370-23-019203.md) | [24.7](/filings/0001558370-25-001826.md) | [23.6](/filings/0001558370-24-007642.md) | [22.7](/filings/0001558370-24-011616.md) | [33.4](/filings/0001558370-24-015531.md) | [36.0](/filings/0001104659-26-020562.md) | [36.5](/filings/0001558370-25-006989.md) | [39.0](/filings/0001558370-25-010541.md) | [57.5](/filings/0001104659-25-107829.md) | [63.3](/filings/0001104659-26-092057.md) | [57.0](/filings/0001104659-26-057230.md) | [66.1](/filings/0001104659-26-092057.md) |
| Total liabilities | $m | [23.4](/filings/0001558370-23-019203.md) | [29.1](/filings/0001558370-25-001826.md) | [27.4](/filings/0001558370-24-007642.md) | [26.0](/filings/0001558370-24-011616.md) | [36.4](/filings/0001558370-24-015531.md) | [38.5](/filings/0001104659-26-020562.md) | [41.9](/filings/0001558370-25-006989.md) | [44.4](/filings/0001558370-25-010541.md) | [62.1](/filings/0001104659-25-107829.md) | [67.5](/filings/0001104659-26-092057.md) | [61.0](/filings/0001104659-26-057230.md) | [71.0](/filings/0001104659-26-092057.md) |
| Shareholders' equity | $m | [193](/filings/0001558370-24-015531.md) | [453](/filings/0001104659-26-020562.md) | [430](/filings/0001104659-25-107829.md) | [921](/filings/0001104659-25-107829.md) | [897](/filings/0001104659-25-107829.md) | [865](/filings/0001104659-26-092057.md) | [825](/filings/0001104659-26-092057.md) | [772](/filings/0001104659-26-092057.md) | [770](/filings/0001104659-25-107829.md) | [1,516](/filings/0001104659-26-092057.md) | [1,447](/filings/0001104659-26-092057.md) | [1,354](/filings/0001104659-26-092057.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(20.6) d](/filings/0001558370-24-015531.md) | [(21.7) d](/filings/0001104659-26-020562.md) | [(34.1)](/filings/0001558370-25-006989.md) | [(26.4) d](/filings/0001558370-25-010541.md) | [(19.7) d](/filings/0001104659-25-107829.md) | [(36.5) d](/filings/0001104659-26-020562.md) | [(52.2)](/filings/0001104659-26-057230.md) | [(54.6) d](/filings/0001104659-26-092057.md) | [(51.0) d](/filings/0001104659-25-107829.md) | [(64.4) d](/filings/0001104659-26-020562.md) | [15.2](/filings/0001104659-26-057230.md) | [(120) d](/filings/0001104659-26-092057.md) |
| Capital expenditure | $m | [0.8 d](/filings/0001558370-24-015531.md) | [1.2 d](/filings/0001104659-26-020562.md) | [0.2](/filings/0001558370-25-006989.md) | [0.4 d](/filings/0001558370-25-010541.md) | [0.7 d](/filings/0001104659-25-107829.md) | [0.0 d](/filings/0001104659-26-020562.md) | [0.3](/filings/0001104659-26-057230.md) | [0.2 d](/filings/0001104659-26-092057.md) | [1.6 d](/filings/0001104659-25-107829.md) | [1.5 d](/filings/0001104659-26-020562.md) | [1.2](/filings/0001104659-26-057230.md) | [(0.0) d](/filings/0001104659-26-092057.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | period not labelled (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [9.8](/filings/0001558370-23-019203.md) | [71.7](/filings/0001558370-24-007642.md) | [115](/filings/0001558370-24-011616.md) | [115](/filings/0001558370-24-015531.md) | [140](/filings/0001558370-25-006989.md) | [148](/filings/0001558370-24-011616.md) | [172](/filings/0001104659-25-107829.md) | [172](/filings/0001104659-26-057230.md) | [173](/filings/0001104659-26-092057.md) | [175](/filings/0001104659-25-107829.md) | [217](/filings/0001104659-26-057230.md) | [218](/filings/0001104659-26-092057.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 213,929,572 at 2026-07-31, from the cover of the [10-Q filed 2026-08-06](/filings/0001104659-26-092057.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.